MAPK3 and Alzheimer disease: Subchronic treatment with apigenin in APP/PS1 mice model downregulates BACE, β-CTF, and β-amyloid deposition and restores BDNF expression leading to increased memory and synaptic plasticity by ERK1/2/CREB-mediated prevention of AD [97].